Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 981-986

  Li, Chuan Gang ^a   Li, Mo Lin ^a   Shu, Xiao Hong ^a   Liu, Yong Ji ^a   Wu, Wen Sen ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; Bladder cancer; Fas; Recombinant human interleukin 6 (rhIL 6); T739 mice

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MITOMYCIN C; PROTEIN BCL 2; RECOMBINANT INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED STRAINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 77956232184     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1336-7     Document Type: Article

References (21)

1. T Kishimoto 1989 The biology of interleukin-6 Blood 74 1 10 1:CAS:528:DyaL1MXkvFGjs70%3D 2473791
2. JJ Mule JK McIntosh DM Jablons SA Rosenberg 1990 Antitumor activity of recombinant Interleukin 6 in mice J Exp Med 171 629 636 10.1084/jem.171.3.629 1:CAS:528:DyaK3cXhslKks7Y%3D 2307930
3. JJ Mule MC Custer WD Travis SA Rosenberg 1992 Cellular mechanisms of the antitumor activity of recombinant Interleukin 6 in mice J Immunol 148 2622 2629 1:CAS:528:DyaK38XisFert70%3D 1348521
4. M Petrucci MR Ricciardi C Ariola C Gregory M Ribersani R Savino G Ciliberto A Tafuri 1999 Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1 Ann Hematol 78 13 18 10.1007/s002770050465 1:CAS:528:DyaK1MXhtFCqtro%3D 10037263
5. M Petrucci MR Ricciardi C Gregory L Ciapponi R Savino G Ciliberto A Tafuri 2002 Effects of IL-6 variants in multiple myeloma: growth inhibition and induction of apoptosis in primary cells Leuk Lymphoma 43 2369 2375 10.1080/1042819021000040224 1:CAS:528:DC%2BD3sXhtlyisg%3D%3D 12613526
6. R Minami K Muta C Ilseung Y Abe J Nishimura H Nowata 2000 Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha Exp Hematol 28 244 255 10.1016/S0301-472X(99)00156-3 1:CAS:528: DC%2BD3cXisVaksr8%3D 10720689
7. R Kim M Emi K Tanabe Y Uchida T Toge 2004 The role of FasL and transforming growth factor in tumor progression : molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy Cancer 100 2281 2291 10.1002/cncr.20270 1:CAS:528:DC%2BD2cXltFWqu7s%3D 15160330
8. LE French M Hahne I Viard G Radlgruber R Zanone K Becker C Müller J Tschopp 1996 Fas and FasL in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover J Cell Biol 133 335 343 10.1083/jcb.133.2.335 1:CAS:528:DyaK28Xitlyms7g%3D 8609166
9. TS Griffith T Brunner SM Fletcher DR Green TA Ferguson 1995 Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270 1189 1192 10.1126/science.270.5239.1189 1:CAS:528:DyaK2MXpsVyktLs%3D 7502042
10. S Nagata P Golstein 1995 The Fas death factor Science 267 1449 1456 10.1126/science.7533326 1:CAS:528:DyaK2MXktlClt7w%3D 7533326
11. K Schulze-Osthoff D Ferrari M Los S Wesselborg ME Peter 1998 Apoptosis signaling by death receptors Eur J Biochem 254 439 459 10.1046/j.1432-1327.1998. 2540439.x 1:CAS:528:DyaK1cXktlertrw%3D 9688254
12. BTM Hougardy AGJ van der Zee FAJ van den Heuvel T Timmer EGE de Vries S de Jong 2005 Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid Gynecol Oncol 97 353 364 10.1016/j.ygyno.2005.01.036 1:CAS:528:DC%2BD2MXjs1Clt7w%3D 15863130
13. W Wensen Y Kezheng H Yueming Z Xiaoming Z Dongshen H Daluo 1996 Establishment and study of a transplantable bladder transitional cell carcinoma model (BTT739) in T739 inbred mice Chin J Clin Oncol 23 751 756
14. Z Darzynkiewicz S Bruno G Del Bino W Gorczyca MA Hotz P Lassota F Traganos 1992 Features of apoptotic cells measured by flow cytometry Cytometry 13 795 808 10.1002/cyto.990130802 1:STN:280:DyaK3s%2Fpt1OrtQ%3D%3D 1333943
15. N Nishimoto T Kishimoto 2006 Interleukin 6: from bench to bedside Nat Clin Pract Rheumatol 2 619 626 10.1038/ncprheum0338 1:CAS:528:DC%2BD28Xht1emtLnI 17075601
16. KC Anderson 2001 Novel biologically based therapies for myeloma Cancer J 7 S19 S23 11504280
17. KJ Kallen 2002 The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases Biochim Biophys Acta 1592 323 343 10.1016/S0167-4889(02)00325-7 1:CAS:528:DC%2BD38Xotl2nsrc%3D 12421676
18. D Kagi F Vignaux B Ledermann K Burki V Depratetere S Nagata H Hengartner P Golstein 1994 Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity Science 265 528 530 10.1126/science.7518614 1:STN:280: DyaK2czhtVCgtQ%3D%3D 7518614
19. S Nagata T Suda 1995 Fas and Fas ligand: lpr and gld mutations Immunol Today 16 39 43 10.1016/0167-5699(95)80069-7 1:CAS:528:DyaK2MXjsVyjtrc%3D 7533498
20. H Zhang G Gao G Clayburne HR Schumacher 2005 Elimination of rheumatoid synovium in situ using a Fas ligand 'gene scalpel' Arthritis Res Ther 7 R1235 R1243 10.1186/ar1811 1:CAS:528:DC%2BD2MXht1Wnu7fF 16277676
21. S Cory 1995 Regulation of lymphocyte survival by the bcl-2 gene family Annu Rev Immunol 13 513 543 10.1146/annurev.iy.13.040195.002501 1:CAS:528:DyaK2MXltFamurg%3D 7612233